Abstract
This case report highlights serious permanent sequelae of a malpositioned levonorgestrel
intrauterine device. Initial cervical injury resulted in fistula formation and large
hematoma eventually requiring hysterectomy. Uterine depth less than 5.5 cm should
prompt timely evaluation, and immediate replacement is not advised when there is concern
for injury.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to ContraceptionAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Use of contraception among reproductive-aged women in the United States, 2014 and 2016.F S Rep. 2020; 1: 83-93https://doi.org/10.1016/j.xfre.2020.06.006
- Three-year efficacy and safety of a new 52-mg levonorgestrel-releasing intrauterine system.Contraception. 2015; 92: 10-16https://doi.org/10.1016/j.contraception.2015.04.006
- Perforated intraperitoneal intrauterine contraceptive devices: diagnosis, management, and clinical outcomes.J Minim Invasive Gynecol. 2014; 21: 596-601https://doi.org/10.1016/j.jmig.2013.12.123
- Intrauterine device malposition at the internal iliac vessels.J Minim Invasive Gynecol. 2018; 25: 752https://doi.org/10.1016/j.jmig.2017.08.650
- Giant exophytic cystic adenomyosis with a levonorgestrel containing intrauterine device out of the uterine cavity after uterine myomectomy: a case report.World J Clin Cases. 2020; 8: 188-193https://doi.org/10.12998/wjcc.v8.i1.188
- Pathogenesis of endometriosis: the genetic/epigenetic theory.Fertil Steril. 2019; 111: 327-340https://doi.org/10.1016/j.fertnstert.2018.10.013
Article info
Publication history
Published online: June 19, 2022
Accepted:
June 1,
2022
Received in revised form:
May 22,
2022
Received:
May 5,
2022
Footnotes
Conflict of interest: The Division of Family Planning at the University of Colorado receives research funding from Bayer, Merck and Co., Organon and Chemo Research.
Funding: This project did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Identification
Copyright
© 2022 Elsevier Inc. All rights reserved.
